BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35338357)

  • 1. Iris melanocytic tumours in New Zealand/Aotearoa: presentation, management and outcome in a high UV exposure environment.
    Rapata MEJ; Zhang J; Cunningham WJ; Hadden PW; Patel DV; McGhee CNJ
    Eye (Lond); 2023 Mar; 37(4):692-699. PubMed ID: 35338357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conservative management of suspicious melanocytic lesions of the iris.
    Oxenreiter MM; Lane AM; Jain P; Kim IK; Gragoudas ES
    Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1319-1324. PubMed ID: 30919077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iris melanoma: risk factors for metastasis in 169 consecutive patients.
    Shields CL; Shields JA; Materin M; Gershenbaum E; Singh AD; Smith A
    Ophthalmology; 2001 Jan; 108(1):172-8. PubMed ID: 11150284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with elevated intraocular pressure in eyes with iris melanoma.
    Shields CL; Materin MA; Shields JA; Gershenbaum E; Singh AD; Smith A
    Br J Ophthalmol; 2001 Jun; 85(6):666-9. PubMed ID: 11371484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field).
    Oxenreiter MM; Lane AM; Aronow MB; Shih H; Trofimov AV; Kim IK; Gragoudas ES
    Br J Ophthalmol; 2022 Apr; 106(4):518-521. PubMed ID: 33355171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uveal tumour resection.
    Char DH; Miller T; Crawford JB
    Br J Ophthalmol; 2001 Oct; 85(10):1213-9. PubMed ID: 11567967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
    Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
    Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Melanoma of the iris with recurrent hyphema--course over 32 years].
    Schmidbauer JM; Burk RO; Daus W; Völcker HE
    Klin Monbl Augenheilkd; 1993 Aug; 203(2):117-20. PubMed ID: 8231044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and Therapy of Iris Lesions].
    Mor JM; Koch KR; Heindl LM
    Klin Monbl Augenheilkd; 2017 Dec; 234(12):1541-1554. PubMed ID: 29156467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis and long-term observation after surgical treatment of patients with tumours of the iris].
    Kühn U; Petersen I; Strobel J
    Klin Monbl Augenheilkd; 2013 Dec; 230(12):1230-7. PubMed ID: 24327286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence of iris melanoma after proton beam therapy.
    Sandinha MT; Kacperek A; Errington RD; Coupland SE; Damato B
    Br J Ophthalmol; 2014 Apr; 98(4):484-7. PubMed ID: 24414401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.
    Shields CL; Di Nicola M; Bekerman VP; Kaliki S; Alarcon C; Fulco E; Shields JA
    Ophthalmology; 2018 Jun; 125(6):913-923. PubMed ID: 29342436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton beam radiotherapy of diffuse iris melanoma in 54 patients.
    Willerding GD; Cordini D; Hackl C; Karle B; Lakotka N; Foerster MH; Bechrakis NN; Heufelder J; Moser L; Joussen AM
    Br J Ophthalmol; 2015 Jun; 99(6):812-6. PubMed ID: 25505288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical signs and differential diagnosis of iris melanoma].
    Tóth J
    Magy Onkol; 2005; 49(2):153-5, 158-9. PubMed ID: 16249812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescein angiography of anterior uveal melanocytic tumours.
    Dart JK; Marsh RJ; Garner A; Cooling RJ
    Br J Ophthalmol; 1988 May; 72(5):326-37. PubMed ID: 3395591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plaque radiotherapy for residual or recurrent iris melanoma after surgical resection in 32 cases.
    Shah SU; Shields CL; Bianciotto C; Emrich J; Komarnicky L; Shields JA
    Ophthalmology; 2012 Apr; 119(4):838-842.e2. PubMed ID: 22133794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton Therapy for 166 Patients with Iris Melanoma: Side Effects and Oncologic Outcomes.
    Gollrad J; Böker A; Vitzthum S; Besserer A; Heufelder J; Gauger U; Böhmer D; Budach V; Zeitz O; Joussen AM
    Ophthalmol Retina; 2023 Mar; 7(3):266-274. PubMed ID: 36087876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ring melanoma of the anterior chamber angle: a report of fourteen cases.
    Demirci H; Shields CL; Shields JA; Eagle RC; Honavar S
    Am J Ophthalmol; 2001 Sep; 132(3):336-42. PubMed ID: 11530045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iris melanoma: Review of clinical features, risks, management, and outcomes.
    Cherkas E; Kalafatis NE; Marous MR; Shields CL
    Clin Dermatol; 2024; 42(1):62-70. PubMed ID: 37865279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The surgical approach to the management of anterior uveal melanomas.
    Rospond-Kubiak I; Damato B
    Eye (Lond); 2014 Jun; 28(6):741-7. PubMed ID: 24722505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.